Abstract: An electromedical implant (1), in particular a cardiac pacemaker, comprising a telemetry device at least for the communication of data to an external apparatus (2), which includes a transmitting device with a transmitter, wherein the transmitter includes an oscillator comprising a first transistor (58) and a resonator (60), and a second transistor (59) forming a buffer stage and an antenna driver.

Abstract: The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

Abstract: A method of monitoring patients with at least one electromedical implant, in which at least one first data transmission is effected between the implant provided with a first transmitting/receiving device and at least one external apparatus provided with a second transmitting/receiving device. At least first data are transmitted from the implant to the external apparatus and at least one second data transmission is effected between the external apparatus and at least one central storage arrangement for the storage of first data, by a telecommunication connection which is at least partially made by way of a mobile radio network. The transmission at least of the first data to the central storage arrangement is effected by way of the portion, formed by the mobile radio network, of the telecommunication connection in the form of at least one SM-string (Short Message String).

Abstract: The present invention is directed to the generation of antibodies which preferentially bind to fibrinogen fragments E1, E2 and E3, but exhibit little or no cross-reactivity against fibrin monomer and fibrinogen. Thus, the invention provides synthetic peptides containing defined amino acid sequences corresponding to the carboxy terminal regions of the E fragments which arise as a result of plasmin cleavage of fibrin and fibrinogen. The synthetic peptides may be synthesized chemically, or through genetic manipulations, and may contain additional amino acid sequences which are not contiguous with the defined E fragment sequences.

Abstract: An electromedical implant (1), in particular a cardiac pacemaker, having a close-range telemetry device for data exchange with an external apparatus (2), which includes at least a close-range antenna (47) and a close-range transmitter/receiver unit with a close-range transmitter (44), a telemetry unit (45) connected thereto and an antenna interface device (46) which is connected to the telemetry unit (45) and by way of which the close-range antenna (47) is connected to the close-range transmitter/receiver unit, wherein there is provided a long-range transmitter (48) connected to the telemetry unit (45) to provide a long-range telemetry device.

Abstract: The present invention relates to a process for increasing the FVII sensitivity of a thromboplastin reagent by means of heat treatment.

Abstract: The application relates to a method for determining the anticoagulatory potential of a sample by adding thrombomodulin and thromboplastin in a coagulation test.

Abstract: The present invention relates to a process for increasing the FVII sensitivity of a thromboplastin reagent by means of heat treatment.

Abstract: A patient monitoring system (1) is provided with at least one body sensor (2a) for measuring a physiological parameter, as well as with a body signal processing unit (3) connected downstream from the former and/or a therapy device (2) designed to act on the patient (P), and a mobile radiotelephone end unit (7) operable in a cellular mobile radiotelephone network (1B) for transmitting data from the body signal processing unit or the therapy device to a central monitoring station (1C) and/or from the central monitoring station to the therapy device. A base station coordinate memory unit (13; 13′) and a locator unit (12, 12.1′ through 12.3′) connected to the former serves for the rough determination of the location of the patient based on location information obtained from the current base station connection of the mobile radiotelephone end unit in the mobile radiotelephone network.

Abstract: The invention relates to a process for preparing factor V-deficient plasma, in particular a factor V-deficient plasma from a starting plasma using antibodies, and a deficient plasma which is obtained in this way.

Abstract: The present invention relates to an implantable diagnostic apparatus for determining analytes in body fluids, which comprises a plurality of identical and/or different measurement units for determining an analytic parameter, in which a signal is generated which is specifically related to the variable to be determined and is transmitted by means of suitable measures to a receiver situated outside the body.

Abstract: The invention relates to a process for the production of plasmas with added annexins for use as a control or standard in all functional clotting tests which are used for the detection of a lupus anticoagulant.

Abstract: The invention relates to a method and to a diagnostic agent for detecting hemostasis disturbances, wherein, as a consequence of blood platelet aggregation, clot formation and/or clot dissolution, substances are brought to a distance from each other which permits or prevents an interaction, in particular an energy transfer, between the substances, and the extent of the interaction is measured.

Abstract: The invention relates to a method for carrying out heterogeneous immunoassays, in particular to a method for separating a coated solid phase from a liquid phase by means of precipitation and subsequent centrifugation, with a detectable activity remaining in the liquid phase.

Abstract: Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state.

Abstract: The present invention is directed to the generation of antibodies which preferentially bind to fibrinogen fragments E1, E2, and E3, but exhibit little or no cross-reactivity against fibrin monomer and fibrinogen. Thus, the invention provides synthetic peptides containing defined amino acid sequences corresponding to the carboxy terminal regions of the E fragments which arise as a result of plasmin cleavage of fibrin and fibrinogen. The synthetic peptides may be synthesized chemically, or through genetic manipulations, and may contain additional amino acid sequences which are not contiguous with the defined E fragment sequences.

Abstract: An apparatus 1 serves for treating tumors in particular. This apparatus has, for example, a sensor-actuator head 3 with at least one sensor 10 for determining the acidification of the immediate surroundings of the tumor cells. An active ingredient dispensing device for exerting chemical influence and/or electrodes for exerting physical influence through electrical and/or electromagnetic fields on the tumorous tissue area to be treated are provided on the sensor-actuator head. The sensor(s) 10 as well as the active ingredient dispensing facility and/or the treatment electrodes are connected with a control facility for controlling chemical and/or physical treatment of the tumorous tissue area as a function of measured values.

Abstract: The invention relates to a plasma which can be used as a calibrator in coagulation tests which detect the degradation of factor V by activated protein C, to the preparation of such a plasma and to its use.

Abstract: The present invention relates to a method for detecting disturbances of the protein C/protein S system.

Abstract: The invention relates to antibodies which react with fibrinogen fragments E1, E2 and E3 raised by immunizing with a peptide. The invention also relates to assay methods for proteins containing an epitope which is common to fibrinogen fragments E1, E2 and E3 using these antibodies.